Selected research
Market Structure
Global Alpha-1 Antitrypsin Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Alpha-1 Antitrypsin Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Alpha-1 Antitrypsin Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Alpha-1 Antitrypsin Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Alpha-1 Antitrypsin Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Alpha-1 Antitrypsin Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Alpha-1 Antitrypsin Drugs include Baxter, Kamada, Grifols, CSL Behring, Baxalta, Arrowhead Research Corporation, Applied Genetic Technologies Corp, Alnylam Pharmaceuticals and Abeona Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Alpha-1 Antitrypsin Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Alpha-1 Antitrypsin Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Alpha-1 Antitrypsin Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Alpha-1 Antitrypsin Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Alpha-1 Antitrypsin Drugs Segment by Company
Baxter
Kamada
Grifols
CSL Behring
Baxalta
Arrowhead Research Corporation
Applied Genetic Technologies Corp
Alnylam Pharmaceuticals
Abeona Therapeutics
Alpha-1 Antitrypsin Drugs Segment by Type
Parenteral
Inhalation
Alpha-1 Antitrypsin Drugs Segment by Application
Drugstore
Hospital
Others
Alpha-1 Antitrypsin Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha-1 Antitrypsin Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alpha-1 Antitrypsin Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha-1 Antitrypsin Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Alpha-1 Antitrypsin Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alpha-1 Antitrypsin Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Alpha-1 Antitrypsin Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Alpha-1 Antitrypsin Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Parenteral
- Inhalation
Applications
- Drugstore
- Hospital
- Others
Companies covered
- Baxter
- Kamada
- Grifols
- CSL Behring
- Baxalta
- Arrowhead Research Corporation
- Applied Genetic Technologies Corp
- Alnylam Pharmaceuticals
- Abeona Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Alpha-1 Antitrypsin Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Alpha-1 Antitrypsin Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Alpha-1 Antitrypsin Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Alpha-1 Antitrypsin Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Alpha-1 Antitrypsin Drugs Market Dynamics
- 2.1 Alpha-1 Antitrypsin Drugs Industry Trends
- 2.2 Alpha-1 Antitrypsin Drugs Industry Drivers
- 2.3 Alpha-1 Antitrypsin Drugs Industry Opportunities and Challenges
- 2.4 Alpha-1 Antitrypsin Drugs Industry Restraints
3 Alpha-1 Antitrypsin Drugs Market by Manufacturers
- 3.1 Global Alpha-1 Antitrypsin Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Alpha-1 Antitrypsin Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Alpha-1 Antitrypsin Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Alpha-1 Antitrypsin Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Alpha-1 Antitrypsin Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Alpha-1 Antitrypsin Drugs Manufacturers, Product Type & Application
- 3.7 Global Alpha-1 Antitrypsin Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Alpha-1 Antitrypsin Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Alpha-1 Antitrypsin Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Alpha-1 Antitrypsin Drugs Tier 1, Tier 2, and Tier 3
4 Alpha-1 Antitrypsin Drugs Market by Type
- 4.1 Alpha-1 Antitrypsin Drugs Type Introduction
- 4.1.1 Parenteral
- 4.1.2 Inhalation
- 4.2 Global Alpha-1 Antitrypsin Drugs Sales by Type
- 4.2.1 Global Alpha-1 Antitrypsin Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Alpha-1 Antitrypsin Drugs Sales by Type (2021-2032)
- 4.2.3 Global Alpha-1 Antitrypsin Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Alpha-1 Antitrypsin Drugs Revenue by Type
- 4.3.1 Global Alpha-1 Antitrypsin Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Alpha-1 Antitrypsin Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Alpha-1 Antitrypsin Drugs Revenue Market Share by Type (2021-2032)
5 Alpha-1 Antitrypsin Drugs Market by Application
- 5.1 Alpha-1 Antitrypsin Drugs Application Introduction
- 5.1.1 Drugstore
- 5.1.2 Hospital
- 5.1.3 Others
- 5.2 Global Alpha-1 Antitrypsin Drugs Sales by Application
- 5.2.1 Global Alpha-1 Antitrypsin Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Alpha-1 Antitrypsin Drugs Sales by Application (2021-2032)
- 5.2.3 Global Alpha-1 Antitrypsin Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Alpha-1 Antitrypsin Drugs Revenue by Application
- 5.3.1 Global Alpha-1 Antitrypsin Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Alpha-1 Antitrypsin Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Alpha-1 Antitrypsin Drugs Revenue Market Share by Application (2021-2032)
6 Global Alpha-1 Antitrypsin Drugs Sales by Region
- 6.1 Global Alpha-1 Antitrypsin Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Alpha-1 Antitrypsin Drugs Sales by Region (2021-2032)
- 6.2.1 Global Alpha-1 Antitrypsin Drugs Sales by Region (2021-2026)
- 6.2.2 Global Alpha-1 Antitrypsin Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Alpha-1 Antitrypsin Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Alpha-1 Antitrypsin Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Alpha-1 Antitrypsin Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Alpha-1 Antitrypsin Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Alpha-1 Antitrypsin Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Alpha-1 Antitrypsin Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Alpha-1 Antitrypsin Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Alpha-1 Antitrypsin Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Alpha-1 Antitrypsin Drugs Revenue by Region
- 7.1 Global Alpha-1 Antitrypsin Drugs Revenue by Region
- 7.1.1 Global Alpha-1 Antitrypsin Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Alpha-1 Antitrypsin Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Alpha-1 Antitrypsin Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Alpha-1 Antitrypsin Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Alpha-1 Antitrypsin Drugs Revenue (2021-2032)
- 7.2.2 North America Alpha-1 Antitrypsin Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Alpha-1 Antitrypsin Drugs Revenue (2021-2032)
- 7.3.2 Europe Alpha-1 Antitrypsin Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Alpha-1 Antitrypsin Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Alpha-1 Antitrypsin Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Alpha-1 Antitrypsin Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Alpha-1 Antitrypsin Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Baxter
- 8.1.1 Baxter Company Information
- 8.1.2 Baxter Business Overview
- 8.1.3 Baxter Alpha-1 Antitrypsin Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Baxter Alpha-1 Antitrypsin Drugs Product Portfolio
- 8.1.5 Baxter Recent Developments
- 8.2 Kamada
- 8.2.1 Kamada Company Information
- 8.2.2 Kamada Business Overview
- 8.2.3 Kamada Alpha-1 Antitrypsin Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Kamada Alpha-1 Antitrypsin Drugs Product Portfolio
- 8.2.5 Kamada Recent Developments
- 8.3 Grifols
- 8.3.1 Grifols Company Information
- 8.3.2 Grifols Business Overview
- 8.3.3 Grifols Alpha-1 Antitrypsin Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Grifols Alpha-1 Antitrypsin Drugs Product Portfolio
- 8.3.5 Grifols Recent Developments
- 8.4 CSL Behring
- 8.4.1 CSL Behring Company Information
- 8.4.2 CSL Behring Business Overview
- 8.4.3 CSL Behring Alpha-1 Antitrypsin Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 CSL Behring Alpha-1 Antitrypsin Drugs Product Portfolio
- 8.4.5 CSL Behring Recent Developments
- 8.5 Baxalta
- 8.5.1 Baxalta Company Information
- 8.5.2 Baxalta Business Overview
- 8.5.3 Baxalta Alpha-1 Antitrypsin Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Baxalta Alpha-1 Antitrypsin Drugs Product Portfolio
- 8.5.5 Baxalta Recent Developments
- 8.6 Arrowhead Research Corporation
- 8.6.1 Arrowhead Research Corporation Company Information
- 8.6.2 Arrowhead Research Corporation Business Overview
- 8.6.3 Arrowhead Research Corporation Alpha-1 Antitrypsin Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Arrowhead Research Corporation Alpha-1 Antitrypsin Drugs Product Portfolio
- 8.6.5 Arrowhead Research Corporation Recent Developments
- 8.7 Applied Genetic Technologies Corp
- 8.7.1 Applied Genetic Technologies Corp Company Information
- 8.7.2 Applied Genetic Technologies Corp Business Overview
- 8.7.3 Applied Genetic Technologies Corp Alpha-1 Antitrypsin Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Applied Genetic Technologies Corp Alpha-1 Antitrypsin Drugs Product Portfolio
- 8.7.5 Applied Genetic Technologies Corp Recent Developments
- 8.8 Alnylam Pharmaceuticals
- 8.8.1 Alnylam Pharmaceuticals Company Information
- 8.8.2 Alnylam Pharmaceuticals Business Overview
- 8.8.3 Alnylam Pharmaceuticals Alpha-1 Antitrypsin Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Alnylam Pharmaceuticals Alpha-1 Antitrypsin Drugs Product Portfolio
- 8.8.5 Alnylam Pharmaceuticals Recent Developments
- 8.9 Abeona Therapeutics
- 8.9.1 Abeona Therapeutics Company Information
- 8.9.2 Abeona Therapeutics Business Overview
- 8.9.3 Abeona Therapeutics Alpha-1 Antitrypsin Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Abeona Therapeutics Alpha-1 Antitrypsin Drugs Product Portfolio
- 8.9.5 Abeona Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Alpha-1 Antitrypsin Drugs Value Chain Analysis
- 9.1.1 Alpha-1 Antitrypsin Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Alpha-1 Antitrypsin Drugs Production Mode & Process
- 9.2 Alpha-1 Antitrypsin Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Alpha-1 Antitrypsin Drugs Distributors
- 9.2.3 Alpha-1 Antitrypsin Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst